山东山大华特科技股份有限公司 2014 年第一季度报告正文 所有董事均出席了审议本次季报的董事会会议。 公司负责人张兆亮、主管会计工作负责人王庆湘及会计机构负责人宋兵声明：保证季度 报告中财务报表的真实、准确、完整。 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 山东山大华特科技股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | | --- | --- | --- | --- | --- | | | | | 增减（%） | | | 营业收入（元） | 308,852,178.71 | 231,251,061.21 | | 33.56 | | 归属于上市公司股东的净利润（元） | 48,675,242.98 | 37,124,539.21 | | 31.11 | | 归属于上市公司股东的扣除 ...

Financial Performance - The company's operating revenue for 2013 was CNY 1,095,341,746.95, representing a 31.93% increase from CNY 830,249,955.17 in 2012[22]. - The net profit attributable to shareholders for 2013 was CNY 153,280,357.19, up 26.06% from CNY 121,590,667.17 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was CNY 152,158,513.59, reflecting a 26.18% increase compared to CNY 120,586,531.24 in 2012[22]. - The net cash flow from operating activities reached CNY 216,052,537.93, an increase of 32.15% from CNY 163,484,225.22 in the prior year[22]. - Basic earnings per share for 2013 were CNY 0.85, a 26.87% increase from CNY 0.67 in 2012[22]. - Total operating revenue for pharmaceutical products reached CNY 703,428,587.49, with a gross margin of 86.63%, reflecting a 27.27% increase year-on-year[50]. - The company achieved an operating revenue of CNY 1.095 billion in 2013, representing a year-on-year growth of 31.93% driven by increased sales in pharmaceuticals and environmental protection businesses[30]. - The company reported a total of CNY 778,315,340.45 in total operating costs, which is a 35.7% increase from CNY 574,262,412.41 in the previous year[182]. Assets and Liabilities - Total assets at the end of 2013 amounted to CNY 1,591,741,310.40, an 18.62% increase from CNY 1,341,876,832.74 at the end of 2012[22]. - The total liabilities amounted to CNY 431,627,444.39, an increase from CNY 395,826,385.86 in the previous year[176]. - The company's total cash and cash equivalents increased by CNY 12,635,464.50, a decrease of 89.69% compared to the previous year[43]. - The company's total liabilities increased significantly due to debt repayment and dividend distributions, resulting in a net cash flow from financing activities of -CNY 137.68 million[30]. - The total equity attributable to shareholders increased to CNY 768,263,396.49 from CNY 633,255,484.90, reflecting a growth of 21.3%[176]. Research and Development - Research and development investment rose to CNY 31.58 million, a 47.33% increase, reflecting enhanced focus on pharmaceutical and environmental product development[30]. - In 2013, the company's R&D expenditure was CNY 31,583,939.76, accounting for 4.11% of net assets and 2.88% of operating revenue, representing a 47.33% increase compared to the previous year[41]. - The company received 21 authorized intellectual property rights in 2013, including 4 national invention patents and 14 utility model patents[27]. Market and Competition - The company anticipates continued growth in the pharmaceutical industry driven by factors such as an aging population and improved healthcare policies[67]. - The company faces significant competition, leading to fluctuations in operational performance, and aims to enhance competitiveness through brand building and market-oriented strategies[72]. - The environmental engineering segment reported a revenue increase of 75.54% and a net profit increase of 58.43% year-over-year[63]. Corporate Governance and Management - The company has established a sound profit distribution policy and governance structure, ensuring compliance with relevant regulations[141]. - The company has not made any major accounting errors or restatements during the reporting period[74]. - The company has engaged in multiple investor communications, discussing its basic situation with various asset management firms[88]. - The company maintains complete independence from its controlling shareholder in terms of personnel, assets, and finances[151]. Employee and Remuneration - As of December 31, 2013, the company employed a total of 2,469 staff, with 39.89% being technical personnel[133]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 4.9456 million[128]. - The company adheres to a compensation policy linking employee income to company performance, with total wages determined by operational status and market conditions[139]. Future Plans and Strategies - The company aims to strengthen its core competitive capabilities and enhance sustainable development through continuous innovation and market expansion[53]. - The company plans to apply for a financing credit limit of 200 million yuan from commercial banks in 2014[71]. - The establishment of a new subsidiary for the production and sales of special rubberized asphalt products is expected to increase profitability[65].